Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES

News & Events:ABMD

ABIOMED INC

325.98Down -11.80 (-3.4934 %)as of 1:00:00pm ET 11/26/2021

Quotes delayed at least 15 min. Log in for real time quote.

Log in for more news Show all article details.Expand all| Hide all article details.Collapse all
  1. Show article details.

    Abiomed to Present at Upcoming Investor Conferences

    Business Wire – 7:00 AM ET 11/18/2021

    ABIOMED (ABMD), Inc., a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens Annual Investment Conference 2021 on Wednesday, December 1, 2021, at 3:00pm ET and at the Piper Sandler Virtual Healthcare Conference on December 2, 2021, at 11:00am ET.
  2. Show article details.

    Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes

    Business Wire – 8:05 AM ET 11/04/2021

    The final results of the PROTECT III and Restore EF prospective studies demonstrate improved outcomes for high-risk PCI patients with the use of Impella heart pumps.
  3. Show article details.

    Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines

    Business Wire – 8:02 AM ET 11/03/2021

    The 2021 guidelines of the European Society of Cardiology for treatment of acute heart failure patients, including patients in cardiogenic shock, raise the recommendation level for short-term mechanical circulatory support systems such as Impella heart pumps from Class IIb to Class IIa. This press release features multimedia.
  4. Show article details.

    TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology

    Business Wire – 7:58 AM ET 11/01/2021

    The robust, high-quality data and clinical studies supporting the use of Abiomed's Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure patients will be showcased at Transcatheter Cardiovascular Therapeutics 2021, the annual scientific symposium of the Cardiovascular Research Foundation. This press release features multimedia.
  5. Show article details.

    BRIEF-Abiomed Announces Q2 FY 2022 Revenue Of $248 Million, Up 18% Year Over Year

    Reuters – 8:22 AM ET 10/28/2021

    ABIOMED Inc (ABMD): * ABIOMED ANNOUNCES Q2 FY 2022 REVENUE OF $248 MILLION, UP 18% YEAR OVER YEAR. * Q2 NON-GAAP EARNINGS PER SHARE $1.03. * Q2 GAAP EARNINGS PER SHARE $1.24. * Q2 REVENUE ROSE 18 PERCENT TO $248 MILLION. * ABIOMED (ABMD) - GIVEN DELTA RESURGENCE, US HOSPITAL LABOR SHORTAGE, NOW SEES FY22 REVENUE $1,010 MILLION TO $1,030 MILLION, UP 19% TO 22%, RESPECTIVELY VERSUS FY21.
  6. Show article details.

    Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year

    Business Wire – 7:00 AM ET 10/28/2021

    Abiomed, Inc. (ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended September 30, 2021.
  7. Show article details.

    Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification

    Business Wire – 7:00 AM ET 10/07/2021

    Abiomed, Inc (ABMD). announced that on Thursday, October 28, 2021, the Company will release financial results for the second quarter of the fiscal year 2022. To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial 212-2361; the international number is 809-1538.
Page:

Today's and Upcoming Events

  • Jan
    26

    ABMD to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Oct
    28

    ABMD announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Classic Patterns (past 90 days)

PROVIDED BY RECOGNIA, INC.

View All Technical Analysis in Advanced Chart Opens in New Window

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
Copyright 1998–2021 FMR LLC. 
All rights reserved. 
Close
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.